Tumor tissue from metastatic castration-resistant prostate cancer (mCRPC) harbors frequent copy number variations (CNVs) in the PTEN-PI3K-AKT pathway. However, identifying CNVs in plasma cell–free DNA ...

A team of researchers from the Badalona Applied Research Group in Oncology (B·ARGO) and the Urologic Tumours Unit of the Institut Català d'Oncologia (ICO) and the Germans Trias i Pujol Research ...

A new study on the genetic causes of the PTEN Hamartoma Tumour Syndrome (PHTS) has found that inhibitors of the PI3ka pathway, commonly used as anticancer drugs, are also effective against this ...

Immunotherapies have been successful in treating many cancer conditions; however, not much success has yet been achieved in metastatic castrate-resistant prostate cancer (mCRPC). A study published ...

Experts in cell signaling at the Babraham Institute have identified how prostate cancer cells achieve cell growth free from the usual growth cues and regulators. This discovery has implications for ...

ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy A next-generation sequencing–based cfDNA assay was used to profile 231 patients with mCRPC from ...

During development, cells grow, expand, and migrate to generate tissues and organs in a highly controlled manner. Many intracellular pathways—series of signaling cascades within a cell—regulate these ...